On April 28, 2017 CEL-SCI Corporation (NYSE MKT: CVM) reported that it has been notified that it will be granted a new patent on Multikine* (Leukocyte Interleukin, Injection), its investigational cancer immunotherapy, from the European Patent Office (Press release, Cel-Sci, APR 28, 2017, View Source [SID1234518735]). The patent is titled: A METHOD FOR MODULATING HLA CLASS II TUMOR CELL SURFACE EXPRESSION WITH A CYTOKINE MIXTURE. Schedule your 30 min Free 1stOncology Demo! The patent relates to a method for altering the composition of tumor infiltrating mononuclear cells, increasing CD4+/CD8+ ratio, increasing tumor stroma/epithelial ratio, and modulating HLA (Human Leukocyte Antigen) class II expression on a tumor cell surface with Multikine. CEL-SCI believes that this will result in the tumor becoming "visible" to the immune system, culminating in a more robust and sustainable anti-tumor immune response.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Geert Kersten, CEL-SCI Chief Executive Officer, said, "Our patent portfolio for Multikine consists of multiple patents issued in the United States, Europe, China and Japan. In addition to these patents that offer certain protections for Multikine, the method of manufacture for Multikine held by CEL-SCI as trade secret offers additional protections."
About Multikine
Multikine is designed to be a different type of therapy against cancer: one that appears to have the potential to work with the body’s natural immune system in the fight against tumors. Multikine is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase 3 clinical trial as a potential first-line treatment for advanced primary squamous cell carcinoma of the head and neck. The Phase 3 study with Multikine, which remains on partial clinical hold for the enrollment of additional patients, has 928 patients enrolled.
Multikine is also being tested in a Phase 1 study at the University of California, San Francisco (UCSF), as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women. Dr. Joel Palefsky, a world-renowned scientist and Key Opinion Leader in human papilloma virus (HPV) research and the prevention of anal cancer, is the Principal Investigator at UCSF.